Practical challenges in patients with stage III NSCLC receiving checkpoint inhibitors after chemoradiation by Shukla, Nikhil A. & Hanna, Nasser H.
Editorial
For reprint orders, please contact: reprints@futuremedicine.com
Practical challenges in patients with stage III
NSCLC receiving checkpoint inhibitors after
chemoradiation
Nikhil A Shukla*,1 & Nasser H Hanna1
1Division of Hematology/Oncology, Department of Medicine, Indiana University Melvin & Bren Simon Cancer Center, Indianapolis,
IN 46202, USA
*Author for correspondence: nashukla@iu.edu
“The widespread use of CPI after CRT will result in more patients presenting new and difficult
challenges for treating physicians.”
First draft submitted: 17 January 2020; Accepted for publication: 27 January 2020; Published online:
6 February 2020
Keywords: checkpoint inhibitors • chemoradiation • lung cancer
NSCLC accounts for 80% of all lung cancer diagnoses, and approximately a third of patients present with locally
advanced (stage III) disease [1]. The optimal therapy for fit patients with unresectable and/or inoperable stage
III disease has evolved over the last three decades from radiation alone to sequential chemoradiation (CRT) to
concurrent CRT followed by checkpoint inhibitor therapy (CPI). The recently reported PACIFIC trial generated
a paradigm shift in the treatment of such patients, with a 3-year overall survival (OS) of 57% for patients receiving
consolidation durvalumab compared with 43.5% for those receiving placebo [2–4]. Similar outcomes were reported
with consolidation pembrolizumab in a Hoosier Cancer Research Network (HCRN) Phase II Trial [5]. In this
article, we explore key clinical challenges that arise when treating patients with consolidation CPI after CRT for
patients with stage III NSCLC; namely, the management of CPI-related pneumonitis, timing of consolidation CPI
and their role in patients with PD-L1 TPS <1% and distinguishing local progression versus pseudoprogression.
Radiation versus checkpoint inhibitor-induced pneumonitis: risk factors & management
Prior to the reporting of the PACIFIC trial and the HCRN LUN 14-179 trial, the safety of administering
consolidation CPI after CRT was unknown. A primary safety concern with this strategy included the risk of
developing life-threatening pneumonitis. CRT alone for the treatment of stage III NSCLC results in a 5–15% rate
of symptomatic pneumonitis. Furthermore, CPI causes symptomatic pneumonitis in approximately 5% of patients
treated for stage IV NSCLC [6,7]. The risk factors for radiation and CPI-induced pneumonitis include the addition
of chemotherapy (concurrently with radiation and as consolidation to CRT), higher volume of lung receiving
radiation and underlying interstitial lung disease [8,9]. Distinguishing CPI-induced pneumonitis from radiation-
induced pneumonitis can be challenging. Both treatment modalities cause pneumonitis early (typically within
12 weeks of treatment exposure) and result in similar symptoms of cough, wheezing, dyspnea and fever [9,10].
Computed tomography findings may differentiate the likely etiology. Key radiographic features for radiation-
induced pneumonitis include localized consolidative ground-glass opacities confined to the radiation treatment
fields, whereas CPI-induced pneumonitis may be more diffuse and tend to involve the lower lung fields [11].
Although the initial management of radiation and CPI-induced pneumonitis involves the use of corticosteroids,
the dose and duration can differ. Grade 1 pneumonitis constitutes asymptomatic radiographic findings and requires
no treatment. Grade 2 CPI-induced pneumonitis is symptomatic but does not require supplemental oxygen
support. Patients should be treated with 0.5–1.0 mg/kg of prednisone until complete resolution of symptoms to
baseline. Following symptom resolution, prednisone should be tapered over a minimum of 2 weeks to prevent a
rebound of pneumonitis symptoms. In the event of grade 3 or 4 CPI-induced pneumonitis, patients should be
treated with 1–2 mg/kg of prednisone, depending on the severity of the clinical scenario. Such patients should
usually be hospitalized, and pulmonary and infectious disease evaluations are warranted as atypical viral and
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fungal infections as well as pre-existing pulmonary diseases such as bronchiolitis obliterans organizing pneumonia,
cryptogenic organizing pneumonia and sarcoidosis can have similar clinical presentations. Assuming there is clinical
improvement; the dose of prednisone should be maintained until resolution of symptoms and followed by a slow
taper over 4 weeks or more. If clinical improvement is not apparent after a few days to a week, infliximab may be
administered and repeated in 1–2 weeks [12]. While patients are receiving>20 mg/day of prednisone, pneumocystis
jirovecii prophylaxis should be administered. Once pneumonitis has resolved, patients who experienced grade 1–2
pneumonitis can be re-challenged with CPI. However, we recommend that patients who experience grade ≥3
pneumonitis should not be re-challenged with CPI.
Optimal time to initiate checkpoint inhibitor consolidation
The optimal time to initiateCPI followingCRT in patients with stage IIINSCLC is not clearly defined. Patients with
stage III NSCLC enrolled in the PACIFIC trial were randomized to durvalumab or placebo within 1–42 days after
completing CRT. In an unplanned, retrospective, subset analysis, those patients who received durvalumab≤2 weeks
from completing CRT had improved progression-free survival (PFS; hazard ratio, 0.39; 95% CI: 0.26–0.58)
compared with those who received durvalumab >2 weeks after completing CRT (hazard ratio, 0.63, 95% CI:
0.49–0.80) [3]. In contrast, the HCRN trial enrolled patients 28–56 days after CRT to receive consolidation
pembrolizumab. An unplanned, retrospective, subset analysis from this trial suggested no difference in any efficacy
end point (time to metastatic disease or death, PFS or OS) for those receiving pembrolizumab 4–6 weeks after
CRT compared with those receiving it 6–8 weeks after CRT [5]. Therefore, no conclusive statements can be made
regarding the optimal timing of CPI after CRT. Those patients who received durvalumab soon after CRT may
have been a more fit patient population with fewer toxicities from CRT compared with those patients requiring
a longer period of recovery. The HCRN trial results suggest no detriment in delaying CPI up to 8 weeks to
recover from toxicities of CRT. The ongoing PACIFIC-2 trial, which randomizes patients with stage III NSCLC to
receive concurrent durvalumab plus CRT followed by durvalumab versus CRT followed by durvalumab, will help
determine the optimal timing of CPI following CRT [13]. Until such results are known, it is our practice to allow
up to 8 weeks for recovery prior to initiating CPI for patients who have experienced significant toxicity to CRT.
Those who are more fit and have few toxicities from CRT can safely initiate CPI sooner, including within 2 weeks
of completing CRT.
The role of consolidation checkpoint inhibitor therapy in patients with PD-L1 ≤1%
In the PACIFIC trial, approximately 30% of patients had a PD-L1 TPS of <1% [2]. Although there appears
to be an increased efficacy for CPI in patients with PD-L1 positive tumors who have stage IV NSCLC, the
impact of PD-L1 score on the outcomes of patients with stage III NSCLC receiving CRT followed by CPI is
less well defined. The PACIFIC trial demonstrated comparable improvement in PFS and OS in patients with
PD-L1 <25% versus ≥25%. However, in an unplanned subset analysis of patients with PD-L1 <1%, PFS was
superior for those who received consolidation durvalumab (p = not significant), while OS favored those receiving
placebo (p = not significant) [3]. Based on this finding, the European Medical Agency (Amsterdam, Netherlands)
has approved consolidation durvalumab only for patients with tumors expressing PD-L1 ≥1%. The US FDA has
no such restriction. In contrast to durvalumab on the PACIFIC trial, the efficacy of consolidation pembrolizumab
in the HCRN trial was similar for patients regardless of PD-L1 score [5]. Our practice is to treat patients with
consolidation CPI after CRT, regardless of PD-L1 status on the initial tumor biopsy. We believe that baseline tumor
PD-L1 score may not be an accurate indicator of consolidation CPI efficacy. CRT increases the activity of cytotoxic
T cells and upregulates expression of PD-L1 on tumor cells (including on cells that are PD-L1 negative), thereby
sensitizing tumors to CPI [14]. Furthermore, discordant PD-L1 scores have been reported between primary tumor
and metastatic sites or regional lymph nodes [15]. Finally, there is an increasing evidence that other biomarkers may
also be predictive of response to CPI, including tumor mutational burden, CD4/8 ratios and even individual gene
mutations such as STK11 [16].
Distinguishing true progression from pseudoprogression
As the use of consolidation CPI after CRT becomes routine, physicians will be challenged in interpreting radio-
graphic changes that evolve over time. Pseudoprogression is an established phenomenon that occurs in approximately
5% of patients receiving CPI [17]. Distinguishing pseudoprogression from evolving radiation fibrosis or localized
true progression is difficult. Pseudoprogression is usually transient and not associated with clinical deterioration.
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Therefore, caution should be heeded in declaring patients to have progressive disease and prematurely initiating
salvage interventions. It is our practice to document pathological recurrence or clear and convincing clinical pro-
gression before initiating salvage therapy. Utilizing the iRECIST criteria, rather than RECIST is essential when
considering whether a patient has experienced treatment failure. The iRECIST criteria require confirmation of
progressive disease 4 weeks after the initial signs of progression or new disease [18].
Consolidation CPI following CRT has resulted in unprecedented increases in survival outcomes for patients
with stage III NSCLC. The widespread use of CPI after CRT will result in more patients presenting new and
difficult challenges for treating physicians. Key challenges are outlined in this article. In summary, we recommend
vigilance in recognizing CPI-related pneumonitis and early consultation with pulmonologists and infectious disease
physicians as other pulmonary diseases and infections can masquerade as pneumonitis. Patients with grade 2 or
higher pneumonitis should not have steroids tapered until clinical symptoms have resolved or return to baseline.
Second, there is no conclusive evidence that delay of initiating CPI for up to 8 weeks to allow recovery from CRT
toxicities is detrimental. Third, we believe patients with tumors that are PD-L1 <1% should not be excluded from
receiving consolidation CPI after CRT. At last, caution should be heeded when declaring a patient to have locally
progressive disease after CRT and CPI as radiographic findings may be misleading.
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